Orchestra BioMed Holdings, Inc. (OBIO) stock
OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$6.97−0.15 (-2.11%)
Close on Nov 17, 2026Market cap $418.93MP/E –Yield –
Orchestra BioMed r&d expenses
Research and development expenses are spending on new products and technology.
Orchestra BioMed's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.22M, up 26.7% year over year. For fiscal 2025 it was $58.19M, up 35.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.19M | +35.9% |
| FY2024 | Dec 31, 2024 | $42.80M | +26.6% |
| FY2023 | Dec 31, 2023 | $33.82M | +54.1% |
| FY2022 | Dec 31, 2022 | $21.95M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.59M | +19.8% |
| Q1 FY2026 | Mar 31, 2026 | $15.78M | +17.1% |
| Q4 FY2025 | Dec 31, 2025 | $16.82M | +53.3% |
| Q3 FY2025 | Sep 30, 2025 | $14.03M | +21.0% |
| Q2 FY2025 | Jun 30, 2025 | $13.85M | +24.5% |
| Q1 FY2025 | Mar 31, 2025 | $13.48M | +48.0% |
| Q4 FY2024 | Dec 31, 2024 | $10.97M | +28.9% |
| Q3 FY2024 | Sep 30, 2024 | $11.60M | +35.5% |
| Q2 FY2024 | Jun 30, 2024 | $11.13M | +30.9% |
| Q1 FY2024 | Mar 31, 2024 | $9.11M | +10.4% |
| Q4 FY2023 | Dec 31, 2023 | $8.51M | +12.8% |
| Q3 FY2023 | Sep 30, 2023 | $8.56M | +45.1% |
| Q2 FY2023 | Jun 30, 2023 | $8.50M | +69.0% |
| Q1 FY2023 | Mar 31, 2023 | $8.25M | +137.6% |
| Q4 FY2022 | Dec 31, 2022 | $7.54M | – |
| Q3 FY2022 | Sep 30, 2022 | $5.90M | – |
| Q2 FY2022 | Jun 30, 2022 | $5.03M | – |
| Q1 FY2022 | Mar 31, 2022 | $3.47M | – |
See a number that looks wrong?